Skip to Main Content
Imvax
  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
    • Scientific Advisors
  • Our Science
    • Overview
    • Our GoldspireTM Platform
    • Advantages
    • Publications
  • Pipeline
    • Overview
    • Imvax Programs
      • IGV-001
      • IHC-001
      • IUC-001
      • ICC-001
      • IEC-001
      • IOC-001
    • Clinical Trials
  • News & Events
  • Culture & Careers
    • Our People
    • Benefits
    • Career Opportunities

News & Partnering

Press releases

Year
  • 2022
  • 2021
  • 2020
  • 2019
November 10, 2022

Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types

October 6, 2022

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 SITC Meeting

September 29, 2022

Imvax Presents New Data on Personalized Whole-Tumor Derived Immunotherapeutic Platform at 2022 International Cancer Immunotherapy Conference

September 22, 2022

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference

In the News

Year
  • 2022
  • 2021
  • 2020
  • 2019
August 11, 2022 | Philadelphia Business Journal

Imvax Named as a PHL Inno Inaugural Fire Awards Honoree

July 5, 2022 | Philadelphia Business Journal,

Life sciences startup leaders talk about challenges of growing in Philadelphia

Upcoming Events

None at this time, stay tuned!

601 Walnut Street, Suite 440W, Philadelphia, PA 19106
267-900-4110
contact@imvax.com

  • Careers at Imvax
  • Privacy Policy
  • Terms of Use
  • LinkedIn
  • Twitter
© Copyright 2023 Imvax®, Inc. All rights reserved.